Concepts (197)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 11 | 2023 | 53 | 3.970 |
Why?
|
| Community Pharmacy Services | 6 | 2022 | 24 | 3.890 |
Why?
|
| Pharmacy | 5 | 2023 | 30 | 3.190 |
Why?
|
| Pharmaceutical Services | 5 | 2023 | 21 | 2.800 |
Why?
|
| Pharmacies | 3 | 2023 | 21 | 2.500 |
Why?
|
| Professional Role | 6 | 2022 | 40 | 1.810 |
Why?
|
| Pulmonary Embolism | 4 | 2018 | 32 | 1.430 |
Why?
|
| Atrial Fibrillation | 5 | 2018 | 101 | 1.410 |
Why?
|
| Students, Pharmacy | 2 | 2021 | 47 | 1.390 |
Why?
|
| Asthma | 4 | 2020 | 380 | 1.320 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 144 | 1.270 |
Why?
|
| Telemedicine | 2 | 2020 | 182 | 1.140 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 276 | 1.120 |
Why?
|
| Humans | 43 | 2024 | 37093 | 1.000 |
Why?
|
| Stroke | 5 | 2018 | 286 | 0.890 |
Why?
|
| Case Management | 1 | 2022 | 20 | 0.840 |
Why?
|
| Health Facilities | 1 | 2022 | 27 | 0.830 |
Why?
|
| Warfarin | 3 | 2018 | 64 | 0.820 |
Why?
|
| Research Personnel | 1 | 2023 | 155 | 0.790 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 20 | 0.790 |
Why?
|
| Health Care Costs | 2 | 2019 | 77 | 0.790 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 55 | 0.780 |
Why?
|
| Influenza, Human | 1 | 2022 | 83 | 0.760 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2020 | 3 | 0.760 |
Why?
|
| Hospital Mortality | 3 | 2017 | 187 | 0.750 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 643 | 0.730 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 49 | 0.710 |
Why?
|
| Ambulatory Care | 1 | 2020 | 75 | 0.700 |
Why?
|
| Drugs, Generic | 1 | 2019 | 4 | 0.690 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 9 | 0.690 |
Why?
|
| Prescription Drugs | 1 | 2019 | 30 | 0.670 |
Why?
|
| United States | 11 | 2023 | 4223 | 0.670 |
Why?
|
| Internship and Residency | 1 | 2020 | 125 | 0.670 |
Why?
|
| Benzazepines | 2 | 2016 | 32 | 0.660 |
Why?
|
| Social Values | 1 | 2018 | 30 | 0.660 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 485 | 0.650 |
Why?
|
| Stroke Volume | 2 | 2016 | 89 | 0.640 |
Why?
|
| Quality of Life | 2 | 2020 | 481 | 0.610 |
Why?
|
| Glucosides | 1 | 2017 | 16 | 0.610 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 21 | 0.610 |
Why?
|
| Anticholesteremic Agents | 1 | 2017 | 23 | 0.600 |
Why?
|
| Hyperlipidemias | 1 | 2017 | 36 | 0.600 |
Why?
|
| Cholesterol, LDL | 1 | 2017 | 68 | 0.600 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 43 | 0.590 |
Why?
|
| Observation | 1 | 2017 | 9 | 0.590 |
Why?
|
| Aged | 12 | 2024 | 6741 | 0.580 |
Why?
|
| Hospitalization | 2 | 2018 | 388 | 0.580 |
Why?
|
| Drug Prescriptions | 2 | 2016 | 41 | 0.570 |
Why?
|
| Cardiovascular Diseases | 3 | 2017 | 664 | 0.550 |
Why?
|
| Resource Allocation | 1 | 2016 | 11 | 0.550 |
Why?
|
| Patient Admission | 1 | 2016 | 41 | 0.540 |
Why?
|
| Databases, Factual | 1 | 2017 | 291 | 0.530 |
Why?
|
| Pyridones | 1 | 2016 | 40 | 0.530 |
Why?
|
| Thiazoles | 1 | 2016 | 74 | 0.530 |
Why?
|
| Pyrazoles | 1 | 2016 | 85 | 0.530 |
Why?
|
| Tetrazoles | 1 | 2015 | 49 | 0.520 |
Why?
|
| Pyridines | 1 | 2016 | 116 | 0.520 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 2721 | 0.500 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 103 | 0.490 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2016 | 86 | 0.480 |
Why?
|
| Smoking Cessation | 1 | 2020 | 517 | 0.470 |
Why?
|
| Idaho | 3 | 2024 | 5 | 0.440 |
Why?
|
| Heart Failure | 1 | 2015 | 235 | 0.430 |
Why?
|
| Workflow | 2 | 2021 | 20 | 0.390 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2020 | 19 | 0.370 |
Why?
|
| Treatment Outcome | 5 | 2018 | 1369 | 0.370 |
Why?
|
| Female | 16 | 2024 | 20969 | 0.370 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2020 | 8 | 0.360 |
Why?
|
| Anticoagulants | 4 | 2018 | 102 | 0.330 |
Why?
|
| Anti-Asthmatic Agents | 2 | 2018 | 31 | 0.310 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2018 | 53 | 0.310 |
Why?
|
| Male | 13 | 2024 | 20025 | 0.310 |
Why?
|
| Markov Chains | 2 | 2018 | 35 | 0.300 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2017 | 44 | 0.290 |
Why?
|
| Chronic Disease | 2 | 2023 | 484 | 0.280 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 191 | 0.280 |
Why?
|
| Risk Assessment | 6 | 2018 | 753 | 0.270 |
Why?
|
| Vaccination | 3 | 2022 | 288 | 0.270 |
Why?
|
| Prospective Studies | 3 | 2018 | 1378 | 0.250 |
Why?
|
| Middle Aged | 6 | 2024 | 10129 | 0.250 |
Why?
|
| Educational Status | 2 | 2023 | 313 | 0.240 |
Why?
|
| Brain Ischemia | 2 | 2018 | 184 | 0.220 |
Why?
|
| Empyema, Pleural | 1 | 2022 | 2 | 0.210 |
Why?
|
| Pleural Effusion | 1 | 2022 | 8 | 0.210 |
Why?
|
| Pleural Diseases | 1 | 2022 | 3 | 0.210 |
Why?
|
| Credentialing | 1 | 2022 | 2 | 0.210 |
Why?
|
| Immunization Programs | 1 | 2022 | 24 | 0.210 |
Why?
|
| Medicare | 2 | 2021 | 195 | 0.210 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2026 | 0.210 |
Why?
|
| Hemorrhage | 2 | 2022 | 45 | 0.210 |
Why?
|
| Immunization | 1 | 2022 | 92 | 0.200 |
Why?
|
| Rural Population | 1 | 2024 | 294 | 0.200 |
Why?
|
| Communicable Diseases | 1 | 2022 | 45 | 0.200 |
Why?
|
| Dietetics | 1 | 2022 | 23 | 0.200 |
Why?
|
| Insurance, Health | 1 | 2022 | 126 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2023 | 446 | 0.190 |
Why?
|
| Authorship | 1 | 2020 | 5 | 0.190 |
Why?
|
| Washington | 1 | 2020 | 31 | 0.190 |
Why?
|
| Oregon | 1 | 2020 | 43 | 0.190 |
Why?
|
| Publications | 1 | 2020 | 7 | 0.190 |
Why?
|
| New Mexico | 1 | 2020 | 31 | 0.190 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 18 | 0.190 |
Why?
|
| Workload | 1 | 2020 | 22 | 0.190 |
Why?
|
| Bibliometrics | 1 | 2020 | 17 | 0.190 |
Why?
|
| Mass Screening | 1 | 2024 | 462 | 0.180 |
Why?
|
| Health Care Surveys | 1 | 2020 | 136 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 70 | 0.170 |
Why?
|
| Adult | 5 | 2024 | 11712 | 0.170 |
Why?
|
| Health Personnel | 1 | 2022 | 228 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 610 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 268 | 0.160 |
Why?
|
| Muscarinic Antagonists | 1 | 2018 | 12 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 28 | 0.160 |
Why?
|
| Thrombectomy | 1 | 2018 | 13 | 0.160 |
Why?
|
| Blood Coagulation | 1 | 2018 | 23 | 0.150 |
Why?
|
| Neoplasms | 2 | 2018 | 1103 | 0.150 |
Why?
|
| Insurance Claim Review | 1 | 2018 | 28 | 0.150 |
Why?
|
| Drug Costs | 1 | 2017 | 28 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 91 | 0.150 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 2379 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2016 | 179 | 0.150 |
Why?
|
| Public Health | 1 | 2020 | 372 | 0.140 |
Why?
|
| Neprilysin | 1 | 2015 | 7 | 0.140 |
Why?
|
| Immune System Diseases | 1 | 2016 | 21 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 400 | 0.130 |
Why?
|
| Biphenyl Compounds | 1 | 2015 | 53 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 69 | 0.130 |
Why?
|
| Drug Combinations | 1 | 2015 | 98 | 0.130 |
Why?
|
| Physicians | 1 | 2017 | 163 | 0.130 |
Why?
|
| Risk Factors | 3 | 2018 | 3562 | 0.130 |
Why?
|
| Heart Rate | 1 | 2016 | 253 | 0.120 |
Why?
|
| Comorbidity | 1 | 2017 | 623 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 204 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2018 | 1492 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 583 | 0.120 |
Why?
|
| Child | 1 | 2022 | 3131 | 0.120 |
Why?
|
| Young Adult | 3 | 2024 | 4268 | 0.110 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 1 | 0.110 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 51 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 95 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 537 | 0.100 |
Why?
|
| Time Factors | 1 | 2016 | 1742 | 0.100 |
Why?
|
| Adolescent | 2 | 2024 | 5363 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2012 | 314 | 0.090 |
Why?
|
| Administration, Inhalation | 2 | 2018 | 80 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 227 | 0.070 |
Why?
|
| Prognosis | 2 | 2018 | 739 | 0.070 |
Why?
|
| Incidence | 2 | 2018 | 922 | 0.060 |
Why?
|
| Vulnerable Populations | 1 | 2024 | 140 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 22 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 25 | 0.050 |
Why?
|
| Health Occupations | 1 | 2021 | 17 | 0.050 |
Why?
|
| Writing | 1 | 2020 | 37 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2022 | 198 | 0.050 |
Why?
|
| Alaska | 1 | 2020 | 53 | 0.050 |
Why?
|
| Faculty | 1 | 2020 | 94 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 265 | 0.040 |
Why?
|
| Mentors | 1 | 2020 | 127 | 0.040 |
Why?
|
| Peer Group | 1 | 2020 | 156 | 0.040 |
Why?
|
| Budesonide | 1 | 2018 | 5 | 0.040 |
Why?
|
| Equipment Safety | 1 | 2018 | 5 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2018 | 55 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 60 | 0.040 |
Why?
|
| ROC Curve | 1 | 2018 | 138 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2020 | 294 | 0.040 |
Why?
|
| Registries | 1 | 2018 | 335 | 0.030 |
Why?
|
| Heart Failure, Systolic | 1 | 2016 | 4 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 2016 | 18 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 38 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 143 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 130 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 224 | 0.030 |
Why?
|
| Students | 1 | 2021 | 519 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1033 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 974 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 142 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2016 | 225 | 0.030 |
Why?
|
| Calsequestrin | 1 | 2012 | 1 | 0.030 |
Why?
|
| Serum Response Factor | 1 | 2012 | 10 | 0.030 |
Why?
|
| Hypercapnia | 1 | 2012 | 8 | 0.030 |
Why?
|
| Facial Pain | 1 | 2012 | 3 | 0.030 |
Why?
|
| Freund's Adjuvant | 1 | 2012 | 14 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2012 | 19 | 0.030 |
Why?
|
| Trigeminal Nuclei | 1 | 2012 | 11 | 0.030 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 33 | 0.030 |
Why?
|
| Nociceptors | 1 | 2012 | 32 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 58 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 70 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2012 | 82 | 0.030 |
Why?
|
| Mice | 2 | 2012 | 5913 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 308 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 893 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 1609 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 1371 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 938 | 0.020 |
Why?
|
| Animals | 2 | 2012 | 15081 | 0.020 |
Why?
|
| Brain | 1 | 2012 | 1346 | 0.020 |
Why?
|